Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

José M. Pérez de la Lastra, Uttpal Anand, Sergio González-Acosta, Manuel R. López, Abhijit Dey, Elza Bontempi, Antonio Morales delaNuez

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a “one health approach” is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.

Original languageEnglish
Article number921483
JournalFrontiers in Immunology
Volume13
DOIs
StatePublished - 2 Jun 2022

Keywords

  • SARS-CoV-2
  • antibiotic discovery
  • antibiotic resistance
  • antimicrobial peptides
  • environmental contamination
  • global health
  • one health approach
  • vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?'. Together they form a unique fingerprint.

Cite this